Next-Generation Coronary Stent

A new coronary stent is designed to offer better visibility and the best-possible delivery.

This TriMaxx stent will be the platform for an investigational drug-eluting stent called ZoMaxx, showcased at the Paris Course on Revascularization (PCR) in Paris (France) in May 2005. The stent was developed by Abbott Vascular (Redwood City, CA, USA).

The TriMaxx coronary stent has extremely thin struts (mesh scaffolding) and an ultra-low crossing profile designed to facilitate stent placement in arteries. The stent was launched in Paris with a full matrix of sizes, including stent diameters ranging from 2.25 mm to 4.0 mm, and lengths ranging from 8 mm to 28 mm. Trimaxx is the first and only bare metal stent platform developed with a tri-layer composite of stainless steel and tantalum designed to enable optimal visibility under x-ray fluoroscopy.

"In my experience, Abbott's TriMaxx stent offers an excellent level of deliverability,” said Alexandre Abizaid, M.D., of Dante Pazzanese Hospital in Sao Paulo (Brazil). "Its thin low-profile design, coupled with the ability to clearly see the product under angiogram (x-ray) should make the TriMaxx a compelling candidate for everyday use and for accurate stent placement in certain challenging cases.” Dr. Abizaid was the first doctor to implant the TriMaxx in patients with diseased coronary arteries.




Related Links:
Abbott Vascular